An initial clinical evaluation or recurrence detection in 64 patients with 15 cancer types revealed that the tumour uptake of [68Ga]Ga-FAP-2286 was much greater than that of [18F]FDG in primary tumours and lymph node metastases (median SUVmax: 11.1 and 10.6 vs. 6.9 and 6.2), and the primary tumour detection rate of [68Ga]Ga-FAP-2286 was significantly greater than that of [18F]FDG PET/CT (100% vs. 80.4%). The gene discussed is FAP; the disease is neoplasm.